Autopsy report · NCT02957019

A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

“Slow progression due to difficulties in finding eligible patients. Competitive clinical trials with innovative agents and new approved products leaddefinitive stop.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 years 3 months after it had already started.
• Ran for about 10 years 2 months before it stopped.
• 6 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Philogen S.p.A.

Sponsor type

Industry

Conditions

Diffuse Large B-cell Lymphoma (DLBCL)

Interventions

L19-IL2 - Ph I; L19-IL2 at RD - Ph II; Rituximab

Participants

6

Sites

1

Countries

Germany

Trials that died the same way

• An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.
  “Trial has been cancelled due to availability of new therapeutic options for patient population” (59% match in meaning)
• Effect of Citalopram on Chest Pain in Patients With Functional Chest Pain
  “The clinical trial has ended prematurely due to low patient recruitment” (58% match in meaning)
• METHOD - Bone Marrow Derived Mononuclear Cells in Chronic Ischemic Disease
  “Due to the slow recruitment process and the progress of newer cell types we decided to stop the trial after the phase 1 (after 10 patients included)” (58% match in meaning)
• Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide
  “PharmaMar has decided to end this study due to the slow recruitment rate of the trial” (57% match in meaning)
• Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors
  “Trial terminated because of lack of efficacy in the short term acute phase” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.